Johnson & Johnson is one of the world’s largest and most diversified healthcare companies. Founded in 1886 in the United States, the company has built a global leadership position in healthcare innovation, driven by a long-standing commitment to scientific excellence, operational discipline, and patient-centered solutions.
Johnson & Johnson maintains a leading global position across most of its therapeutic franchises and medical technology platforms. In 2025, the company reported $94.2 billion in total sales, with approximately $53 billion generated in the U.S. and $40.4 billion internationally The company, currently under the leadership of the Spaniard Joaquin Duato, invested $17.2 billion in R&D in 2024, ranking among the top pharmaceutical investors globally. It currently markets 26 products and platforms generating over $1 billion in annual sales.
Johnson & Johnson secured 27 regulatory approvals in major markets and initiated 17 Phase 3 studies, reinforcing a pipeline strategy aimed at delivering sustained growth through differentiated innovation.
Johnson & Johnson, present in Spain since 1984, is currently conducting more than 180 clinical research projects across the country, involving over 100 hospital centers and approximately 300 investigators, benefiting thousands of patients. This sustained research activity reflects the company’s long-term commitment to advancing therapeutic innovation and strengthening Spain’s clinical development ecosystem.
Madrid offers Johnson & Johnson strategic advantages including proximity to leading hospitals, research centers, regulatory authorities, and a dense network of multinational pharma operators. The region’s integrated healthcare system and strong clinical research environment support the development and testing of innovative therapies.
The company’s presence contributes to Madrid’s position as Spain’s leading region in clinical trials, pharmaceutical production capacity, and healthcare innovation, reinforcing its role as a Southern European hub for life sciences.
Johnson & Johnson combines global scientific leadership with a strong commitment to public health awareness initiatives in Spain. Since 2019, the company has partnered with the Fundación Real Madrid to promote early detection of prostate cancer through the campaign “Que no te pille fuera de juego.”
In parallel, through the “Premios Afectivo Efectivo,” Johnson & Johnson recognizes projects across Spain that improve healthcare humanization, efficiency, and patient-centered outcomes. These awards bring together healthcare professionals, patient associations, institutions, and public stakeholders to highlight best practices.
In 2026, Johnson & Johnson has inaugurated its new corporate headquarters in Pozuelo de Alarcón (Madrid), marking a strategic milestone in its long-standing presence in Spain. The new offices represent a forwardlooking investment aligned with the company’s global transformation and innovation-driven operating model.
The facility will integrate corporate functions across Innovative Medicine and MedTech, strengthening coordination in regulatory affairs, market access strategy, commercial operations, and stakeholder engagement from Madrid. Designed as a modern, collaborative workspace, the headquarters reflects Johnson & Johnson’s commitment to operational excellence, sustainability, and long-term growth in the Spanish market.
Located within one of Southern Europe’s most dynamic pharmaceutical clusters, the new Pozuelo headquarters reinforces Madrid’s attractiveness for multinational healthcare companies and consolidates the region’s role as a strategic life sciences hub within Europe.